{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:50:02Z","timestamp":1779342602267,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Predoctoral research fellowship 2022 from Junta de Castilla y Le\u00f3n","award":["JCYL-EDU\/1868\/2022"],"award-info":[{"award-number":["JCYL-EDU\/1868\/2022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93629-7","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T18:36:02Z","timestamp":1743014162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["SAMHD1 dysfunction impairs DNA damage response and increases sensitivity to PARP inhibition in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Alberto","family":"Rodr\u00edguez-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Quijada-\u00c1lamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"P\u00e9rez-Carretero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana B.","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Arroyo-Barea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"D\u00e1vila-Valls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araceli","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Garc\u00eda de Coca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Benito-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana E.","family":"Rodr\u00edguez-Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas Mar\u00eda","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Hern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"10","key":"93629_CR1","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1172\/JCI64101","volume":"122","author":"G Gaidano","year":"2012","unstructured":"Gaidano, G., Fo\u00e0, R. & Dalla-Favera, R. Molecular pathogenesis of chronic lymphocytic leukemia. J. Clin. Investig. 122(10), 3432\u20133438 (2012).","journal-title":"J. Clin. Investig."},{"issue":"1","key":"93629_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrc2764","volume":"10","author":"T Zenz","year":"2010","unstructured":"Zenz, T., Mertens, D., K\u00fcppers, R., D\u00f6hner, H. & Stilgenbauer, S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat. Rev. Cancer 10(1), 37\u201350 (2010).","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"93629_CR3","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","volume":"54","author":"BA Knisbacher","year":"2022","unstructured":"Knisbacher, B. A. et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat. Genet. 54(11), 1664\u20131674 (2022).","journal-title":"Nat. Genet."},{"issue":"7574","key":"93629_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526(7574), 519\u2013524 (2015).","journal-title":"Nature"},{"issue":"7574","key":"93629_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau, D. A. et al. Mutations driving CLL and their evolution in progression and relapse. Nature 526(7574), 525\u2013530 (2015).","journal-title":"Nature"},{"issue":"7377","key":"93629_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nature10623","volume":"480","author":"DC Goldstone","year":"2011","unstructured":"Goldstone, D. C. et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature 480(7377), 379\u2013382 (2011).","journal-title":"Nature"},{"issue":"51","key":"93629_CR7","doi-asserted-by":"publisher","first-page":"43596","DOI":"10.1074\/jbc.C111.317628","volume":"286","author":"RD Powell","year":"2011","unstructured":"Powell, R. D., Holland, P. J., Hollis, T. & Perrino, F. W. Aicardi-Gouti\u00e8res syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J. Biol. Chem. 286(51), 43596\u201343600 (2011).","journal-title":"J. Biol. Chem."},{"issue":"35","key":"93629_CR8","doi-asserted-by":"publisher","first-page":"14272","DOI":"10.1073\/pnas.1312033110","volume":"110","author":"E Franzolin","year":"2013","unstructured":"Franzolin, E. et al. The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 110(35), 14272\u201314277 (2013).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"93629_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc3981","volume":"15","author":"CK Mathews","year":"2015","unstructured":"Mathews, C. K. Deoxyribonucleotide metabolism, mutagenesis and cancer. Nat. Rev. Cancer 15(9), 528\u2013539 (2015).","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"93629_CR10","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1073\/pnas.1519128113","volume":"113","author":"M Rentoft","year":"2016","unstructured":"Rentoft, M. et al. Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance. Proc. Natl. Acad. Sci. U. S. A. 113(17), 4723\u20134728 (2016).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"93629_CR11","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.celrep.2017.08.008","volume":"20","author":"W Daddacha","year":"2017","unstructured":"Daddacha, W. et al. SAMHD1 promotes DNA end resection to facilitate DNA repair by homologous recombination. Cell Rep. 20(8), 1921\u20131935 (2017).","journal-title":"Cell Rep."},{"issue":"7","key":"93629_CR12","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ng.373","volume":"41","author":"GI Rice","year":"2009","unstructured":"Rice, G. I. et al. Mutations involved in Aicardi-Gouti\u00e8res syndrome implicate SAMHD1 as regulator of the innate immune response. Nat. Genet. 41(7), 829\u2013832 (2009).","journal-title":"Nat. Genet."},{"issue":"R2","key":"93629_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/hmg\/ddp293","volume":"18","author":"YJ Crow","year":"2009","unstructured":"Crow, Y. J. & Rehwinkel, J. Aicardi-Goutie\u2019res syndrome and related phenotypes: Linking nucleic acid metabolism with autoimmunity. Hum. Mol. Genet. 18(R2), 130\u2013136 (2009).","journal-title":"Hum. Mol. Genet."},{"issue":"7","key":"93629_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2013-04-490847","volume":"123","author":"R Clifford","year":"2014","unstructured":"Clifford, R. et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 123(7), 1021\u20131031 (2014).","journal-title":"Blood"},{"issue":"18","key":"93629_CR15","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1182\/blood-2015-05-647578","volume":"126","author":"R Gui\u00e8ze","year":"2015","unstructured":"Gui\u00e8ze, R. et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed\/refractory CLL. Blood 126(18), 2110\u20132117 (2015).","journal-title":"Blood"},{"issue":"2","key":"93629_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. N. Engl. J. Med. 361(2), 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"93629_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v12040382","volume":"12","author":"SA Coggins","year":"2020","unstructured":"Coggins, S. A., Mahboubi, B., Schinazi, R. F. & Kim, B. SAMHD1 functions and human diseases. Viruses 12(4), 1\u201328 (2020).","journal-title":"Viruses"},{"issue":"1","key":"93629_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ng.1032","volume":"44","author":"V Quesada","year":"2012","unstructured":"Quesada, V. et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat. Genet. 44(1), 47\u201352 (2012).","journal-title":"Nat. Genet."},{"issue":"7354","key":"93629_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475(7354), 101\u2013105 (2011).","journal-title":"Nature"},{"issue":"43","key":"93629_CR20","doi-asserted-by":"publisher","first-page":"E10022","DOI":"10.1073\/pnas.1805593115","volume":"115","author":"KM Knecht","year":"2018","unstructured":"Knecht, K. M. et al. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1. Proc. Natl. Acad. Sci. U. S. A. 115(43), E10022\u2013E10031 (2018).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"93629_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nm.4255","volume":"23","author":"C Schneider","year":"2017","unstructured":"Schneider, C. et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat. Med. 23(2), 250\u2013255 (2017).","journal-title":"Nat. Med."},{"issue":"4","key":"93629_CR22","first-page":"879","volume":"56","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Involvement of SAMHD1 in dNTP homeostasis and the maintenance of genomic integrity and oncotherapy (Review). Int. J. Oncol. 56(4), 879\u2013888 (2020).","journal-title":"Int. J. Oncol."},{"issue":"6","key":"93629_CR23","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jmcb\/mju045","volume":"6","author":"L Zannini","year":"2014","unstructured":"Zannini, L., Delia, D. & Buscemi, G. CHK2 kinase in the DNA damage response and beyond. J. Mol. Cell Biol. 6(6), 442\u2013457 (2014).","journal-title":"J. Mol. Cell Biol."},{"issue":"9","key":"93629_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a012716","volume":"5","author":"A Mar\u00e9chal","year":"2013","unstructured":"Mar\u00e9chal, A. & Zou, L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb. Perspect. Biol. 5(9), 1\u201318 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"93629_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.virol.2016.05.002","volume":"495","author":"S Bonifati","year":"2016","unstructured":"Bonifati, S. et al. SAMHD1 controls cell cycle status, apoptosis and HIV-1 infection in monocytic THP-1 cells. Virology 495, 92\u2013100 (2016).","journal-title":"Virology"},{"issue":"3","key":"93629_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2013-204845","volume":"74","author":"S Kretschmer","year":"2015","unstructured":"Kretschmer, S. et al. SAMHD1 prevents autoimmunity by maintaining genome stability. Ann. Rheum. Dis. 74(3), 1\u20138 (2015).","journal-title":"Ann. Rheum. Dis."},{"issue":"16","key":"93629_CR27","doi-asserted-by":"publisher","first-page":"26027","DOI":"10.18632\/oncotarget.15215","volume":"8","author":"I Garc\u00eda-Tu\u00f1\u00f3n","year":"2017","unstructured":"Garc\u00eda-Tu\u00f1\u00f3n, I. et al. The CRISPR\/Cas9 system efficiently reverts the tumorigenic ability of BCR\/ABL in vitro and in a xenograft model of chronic myeloid leukemia. Oncotarget 8(16), 26027\u201326040 (2017).","journal-title":"Oncotarget"},{"key":"93629_CR28","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.3390\/cancers13215328","volume":"13","author":"KA Skelding","year":"2021","unstructured":"Skelding, K. A. & Lincz, L. F. PARP inhibitors and haematological malignancies\u2014Friend or foe?. Cancers 13, 5328 (2021).","journal-title":"Cancers"},{"key":"93629_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.304","author":"M Quijada-\u00c1lamo","year":"2021","unstructured":"Quijada-\u00c1lamo, M. et al. Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia. Clin. Transl. Med. https:\/\/doi.org\/10.1002\/ctm2.304 (2021).","journal-title":"Clin. Transl. Med."},{"issue":"7","key":"93629_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00520-5","volume":"11","author":"M Quijada-\u00c1lamo","year":"2021","unstructured":"Quijada-\u00c1lamo, M. et al. Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression. Blood Cancer J. 11(7), 1\u201311 (2021).","journal-title":"Blood Cancer J."},{"issue":"10","key":"93629_CR31","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1002\/ijc.33235","volume":"147","author":"C P\u00e9rez-Carretero","year":"2020","unstructured":"P\u00e9rez-Carretero, C. et al. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications. Int. J. Cancer 147(10), 2780\u20132792 (2020).","journal-title":"Int. J. Cancer"},{"issue":"7","key":"93629_CR32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/ajh.26578","volume":"97","author":"C P\u00e9rez-Carretero","year":"2022","unstructured":"P\u00e9rez-Carretero, C. et al. TRAF3 alterations are frequent in del-3\u2019IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. Am. J. Hematol. 97(7), 903\u2013914 (2022).","journal-title":"Am. J. Hematol."},{"issue":"10","key":"93629_CR33","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/leu.2011.125","volume":"25","author":"T Herold","year":"2011","unstructured":"Herold, T. et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 25(10), 1639\u20131645 (2011).","journal-title":"Leukemia"},{"issue":"12","key":"93629_CR34","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.3390\/cancers15123095","volume":"15","author":"ES Paik","year":"2023","unstructured":"Paik, E. S., Chang, H. K. & Lee, S. Prevalence of homologous recombination deficiency in first-line PARP inhibitor maintenance clinical trials and further implication of personalized treatment in ovarian cancer. Cancers (Basel) 15(12), 3095 (2023).","journal-title":"Cancers (Basel)"},{"issue":"9","key":"93629_CR35","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.4161\/cc.4.9.2031","volume":"4","author":"T Helleday","year":"2005","unstructured":"Helleday, T., Bryant, H. E. & Schultz, N. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4(9), 1176\u20131178 (2005).","journal-title":"Cell Cycle"},{"issue":"6","key":"93629_CR36","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41375-020-0714-3","volume":"34","author":"M Quijada-\u00c1lamo","year":"2020","unstructured":"Quijada-\u00c1lamo, M. et al. CRISPR\/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia 34(6), 1599\u20131612 (2020).","journal-title":"Leukemia"},{"key":"93629_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pgen.1009523","volume":"17","author":"K Park","year":"2021","unstructured":"Park, K. et al. Aicardi-Gouti\u00e8res syndrome-associated gene SAMHD1 preserves genome integrity by preventing R-loop formation at transcription\u2013replication conflict regions. PLoS Genet. 17, 1\u201324 (2021).","journal-title":"PLoS Genet."},{"issue":"6","key":"93629_CR38","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.3109\/10428194.2013.829919","volume":"55","author":"T Stankovic","year":"2014","unstructured":"Stankovic, T. & Skowronska, A. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk. Lymphoma. 55(6), 1227\u20131239 (2014).","journal-title":"Leuk. Lymphoma."},{"key":"93629_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0134-z","author":"GZ Rassidakis","year":"2018","unstructured":"Rassidakis, G. Z. et al. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer J. https:\/\/doi.org\/10.1038\/s41408-018-0134-z (2018).","journal-title":"Blood Cancer J."},{"issue":"December","key":"93629_CR40","first-page":"1","volume":"11","author":"T Wang","year":"2021","unstructured":"Wang, T. et al. SAMHD1 mutations and expression in mantle cell lymphoma patients. Front. Oncol. 11(December), 1\u201310 (2021).","journal-title":"Front. Oncol."},{"issue":"1","key":"93629_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/ijc.33202","volume":"148","author":"T Roider","year":"2021","unstructured":"Roider, T. et al. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. Int. J. Cancer 148(1), 150\u2013160 (2021).","journal-title":"Int. J. Cancer"},{"issue":"3","key":"93629_CR42","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.17352","volume":"193","author":"I Xagoraris","year":"2021","unstructured":"Xagoraris, I. et al. Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. Br. J. Haematol. 193(3), 488\u2013496 (2021).","journal-title":"Br. J. Haematol."},{"issue":"12","key":"93629_CR43","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nbt.3026","volume":"32","author":"JG Doench","year":"2014","unstructured":"Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32(12), 1262\u20131267 (2014).","journal-title":"Nat. Biotechnol."},{"key":"93629_CR44","unstructured":"CRISPick [Internet]. https:\/\/portals.broadinstitute.org\/gppx\/crispick\/public (2023)."},{"issue":"20","key":"93629_CR45","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20), 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"93629_CR46","doi-asserted-by":"crossref","unstructured":"Hallek. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines (Blood (2008) (111)). Blood.112(13), 5259 (2008).","DOI":"10.1182\/blood-2008-10-186254"},{"key":"93629_CR47","unstructured":"SwimmerPlot GitHub public site [Internet]. https:\/\/cllmap.org\/viz\/swimmer-plot\/ (2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93629-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93629-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93629-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T08:56:56Z","timestamp":1743325016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93629-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93629"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93629-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"2 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the ethics committee of Hospital Universitario de Salamanca and written informed consent was obtained from all participants before they entered the study in accordance to the declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"10446"}}